171 related articles for article (PubMed ID: 38493688)
21. Advances in Modeling the Immune Microenvironment of Colorectal Cancer.
Yoon PS; Del Piccolo N; Shirure VS; Peng Y; Kirane A; Canter RJ; Fields RC; George SC; Gholami S
Front Immunol; 2020; 11():614300. PubMed ID: 33643296
[TBL] [Abstract][Full Text] [Related]
22. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2.
Xu M; Xu X; Pan B; Chen X; Lin K; Zeng K; Liu X; Xu T; Sun L; Qin J; He B; Pan Y; Sun H; Wang S
Mol Cancer; 2019 Sep; 18(1):135. PubMed ID: 31492160
[TBL] [Abstract][Full Text] [Related]
23. Integrative analysis of significant RNA-binding proteins in colorectal cancer metastasis.
Zhou B; Guo R
J Cell Biochem; 2018 Dec; 119(12):9730-9741. PubMed ID: 30132996
[TBL] [Abstract][Full Text] [Related]
24. RNA Binding Protein-Based Model for Prognostic Prediction of Colorectal Cancer.
Li T; Hui W; Halike H; Gao F
Technol Cancer Res Treat; 2021; 20():15330338211019504. PubMed ID: 34080453
[TBL] [Abstract][Full Text] [Related]
25. The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches.
Zafari N; Khosravi F; Rezaee Z; Esfandyari S; Bahiraei M; Bahramy A; Ferns GA; Avan A
J Clin Lab Anal; 2022 Aug; 36(8):e24585. PubMed ID: 35808903
[TBL] [Abstract][Full Text] [Related]
26. LINC00543 promotes colorectal cancer metastasis by driving EMT and inducing the M2 polarization of tumor associated macrophages.
Zheng J; Dou R; Zhang X; Zhong B; Fang C; Xu Q; Di Z; Huang S; Lin Z; Song J; Wang S; Xiong B
J Transl Med; 2023 Feb; 21(1):153. PubMed ID: 36841801
[TBL] [Abstract][Full Text] [Related]
27. CEP63 upregulates YAP1 to promote colorectal cancer progression through stabilizing RNA binding protein FXR1.
Ling H; Cao CH; Han K; Lv YR; Ma XD; Cao JH; Chen JW; Li S; Lin JL; Fang YJ; Pan ZZ; Xie D; Wang FW
Oncogene; 2022 Sep; 41(39):4433-4445. PubMed ID: 35989368
[TBL] [Abstract][Full Text] [Related]
28. Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer.
Janssen JBE; Medema JP; Gootjes EC; Tauriello DVF; Verheul HMW
Cancer Treat Rev; 2022 Sep; 109():102433. PubMed ID: 35905558
[TBL] [Abstract][Full Text] [Related]
29. Single-cell N
Gao Y; Wang H; Chen S; An R; Chu Y; Li G; Wang Y; Xie X; Zhang J
J Transl Med; 2022 May; 20(1):197. PubMed ID: 35509079
[TBL] [Abstract][Full Text] [Related]
30. Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy.
Gomes S; Rodrigues AC; Pazienza V; Preto A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982144
[TBL] [Abstract][Full Text] [Related]
31. A Robust Prognostic Signature of Tumor Microenvironment in Colorectal Cancer.
Liu J; Yu F; Liu Z; Wang X; Li J
Cancer Biother Radiopharm; 2022 Dec; 37(10):963-975. PubMed ID: 34551265
[No Abstract] [Full Text] [Related]
32. Tumor microenvironment involvement in colorectal cancer progression
Novoa Díaz MB; Martín MJ; Gentili C
World J Gastroenterol; 2022 Jul; 28(26):3027-3046. PubMed ID: 36051330
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment.
Zheng X; Ma Y; Bai Y; Huang T; Lv X; Deng J; Wang Z; Lian W; Tong Y; Zhang X; Yue M; Zhang Y; Li L; Peng M
Front Immunol; 2022; 13():984480. PubMed ID: 36389763
[TBL] [Abstract][Full Text] [Related]
34. Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers.
Zabeti Touchaei A; Vahidi S; Samadani AA
Clin Exp Med; 2024 Jan; 24(1):29. PubMed ID: 38294554
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications.
Cao Q; Tian Y; Deng Z; Yang F; Chen E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542332
[TBL] [Abstract][Full Text] [Related]
36. CX3CR1 Acts as a Protective Biomarker in the Tumor Microenvironment of Colorectal Cancer.
Yue Y; Zhang Q; Sun Z
Front Immunol; 2021; 12():758040. PubMed ID: 35140706
[TBL] [Abstract][Full Text] [Related]
37. Cross-Talk Between m
Song W; Ren J; Xiang R; Yuan W; Fu T
Front Immunol; 2022; 13():740960. PubMed ID: 35350786
[TBL] [Abstract][Full Text] [Related]
38. Musashi-2 potentiates colorectal cancer immune infiltration by regulating the post-translational modifications of HMGB1 to promote DCs maturation and migration.
Meng X; Na R; Peng X; Li H; Ouyang W; Zhou W; You X; Li Y; Pu X; Zhang K; Xia J; Wang J; Tang H; Zhuang G; Peng Z
Cell Commun Signal; 2024 Feb; 22(1):117. PubMed ID: 38347600
[TBL] [Abstract][Full Text] [Related]
39. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy.
Bhat AA; Nisar S; Singh M; Ashraf B; Masoodi T; Prasad CP; Sharma A; Maacha S; Karedath T; Hashem S; Yasin SB; Bagga P; Reddy R; Frennaux MP; Uddin S; Dhawan P; Haris M; Macha MA
Cancer Commun (Lond); 2022 Aug; 42(8):689-715. PubMed ID: 35791509
[TBL] [Abstract][Full Text] [Related]
40. Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis.
Guo L; Wang Y; Yang W; Wang C; Guo T; Yang J; Shao Z; Cai G; Cai S; Zhang L; Hu X; Xu Y
Gastroenterology; 2023 Aug; 165(2):414-428.e7. PubMed ID: 37146911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
